Behavioral
Column Health, LLC
Column Health, LLC was paid $32.69M by Medicaid between Jan 2018 and Dec 2024, across 32 billing codes. Its largest line is T1012, Alcohol and/or substance abuse services, skills development — 38% of everything it billed.
33Billing provider infoCOLUMN HEALTH, LLC
LAWRENCE, MA 01843
LAWRENCE, MA 01843
33aNPI1861898934assigned 11/17/2014
33bProvider typeAddiction (Substance Use Disorder) Psychologist
28Total paid$32.69M
24GClaims322,681
24DCodes billed32
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official NIEMAN, AMY controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,859 | $1.29M | |
| 2019 | 43,797 | $4.21M | |
| 2020 | 51,144 | $4.75M | |
| 2021 | 49,724 | $5.03M | |
| 2022 | 68,995 | $7.20M | |
| 2023 | 54,039 | $5.57M | |
| 2024incomplete | 41,123 | $4.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1012 | Alcohol and/or substance abuse services, skills development | 38% | 35,022 | 20,340 | $12.32M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 12% | 40,213 | 23,717 | $3.91M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 11% | 52,850 | 38,457 | $3.54M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 8.0% | 6,323 | 3,433 | $2.62M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 5.1% | 49,372 | 28,845 | $1.68M |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | 4.8% | 8,276 | 2,875 | $1.57M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.5% | 44,437 | 29,119 | $1.48M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3.3% | 14,551 | 13,429 | $1.08M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.1% | 19,483 | 14,616 | $1.01M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 2.6% | 13,164 | 8,245 | $858K |
| J2315 | Injection, naltrexone, depot form, 1 mg | 2.1% | 578 | 556 | $670K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 1.7% | 11,820 | 8,057 | $571K |
20 more codes
| G2068 | Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | 1.1% | 1,575 | $361K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 10,862 | $322K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 1,090 | $150K |
| S0109 | Methadone, oral, 5 mg | <1% | 442 | $125K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,567 | $121K |
| G2079 | Take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 622 | $68K |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | <1% | 4,296 | $63K |
| 99205 | Prolong outpt/office vis | <1% | 579 | $43K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 436 | $40K |
| G2074 | Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 116 | $18K |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 1,104 | $14K |
| 81025 | <1% | 2,010 | $12K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 604 | $11K |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 228 | $10K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 810 | $9K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 26 | $2K |
| G2077 | Periodic assessment; assessing periodically by an otp practitioner and includes a review of moud dosing, treatment response, other substance use disorder treatment needs, responses and patient-identified goals, and other relevant physical, nutrition and psychiatric treatment needs and goals; may be informed by administration of a standardized, evidence-based assessment, or the need and interest for harm reduction interventions and recovery support services (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to each primary code | <1% | 19 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 37 | $1K |
| H0033 | Oral medication administration, direct observation | <1% | 70 | $983.94 |
| 99406 | <1% | 99 | $795.03 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNIEMAN, AMY (DIRECTOR OF CREDENTIALING)
| Provider | Location | Paid |
|---|---|---|
| Brightview, LLC | Cincinnati, OH | $501.08M |
| Brightview LLC | Lynchburg, VA | $31.97M |
| Brightview LLC | Nicholasville, KY | $11.47M |
| Chesapeake Treatment Services LLC | Easton, MD | $5.20M |
| Chesapeake Treatment Services Ocean City LLC | Ocean City, MD | $4.74M |
| Brightview LLC | Lexington, KY | $2.06M |
| Brightview LLC | Cincinnati, OH | $1.13M |
| Brightview LLC | Paris, KY | $1.03M |
| Brightview LLC | Asheboro, NC | $597K |
| Brightview LLC | London, KY | $579K |
| Brightview LLC | Louisville, KY | $29K |
| Brightview LLC | Georgetown, KY | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.